A Phase 1 interventional study of MP-424(H), PEG-IFN-a-2b, RBV and MP-424 (L), PEG-IFN-a-2b, RBV in Hepatitis C, sponsored by Tanabe Pharma Corporation. Completed at 1 site in Japan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Tanabe Pharma Corporation · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing telaprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C.
Among the 39 studies testing telaprevir in Hepatitis C, this one is the 25th largest by enrollment, is one of 8 that started in 2008, is one of 12 in phase 1, and was the 8th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 39 studies testing telaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 9 · Phase 3 13 · Phase 4 5
First in 2005; this study’s year is marked. 8 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 30 across the 39 interventional studies. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 39 have an industry lead sponsor. The 10 most frequent:
Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Tanabe Pharma Corporation has 4 studies filed under Hepatitis C — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing telaprevir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, pharmacokinetics, HCV RNA kinetics, and other viral characteristics after administration of two arms of MP-424 in combination with Peginterferon Alfa 2b (PEG-IFN-a-2b) and Ribavirin (RBV) to patients with chronic hepatitis C.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MP-424(H), PEG-IFN-a-2b, RBV
Drug: MP-424 (L), PEG-IFN-a-2b, RBV
Drug pages: Telaprevir · Peginterferon alfa-2b · Ribavirin
MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
Also known as: Telaprevir
Drug pages: Telaprevir · Peginterferon alfa-2b · Ribavirin
MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
Also known as: Telaprevir
Cmax (Maximum Observed Concentration in Plasma) of MP-424
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
Time frame: Data were collected at Day1 to Day85
Tmax (Time of Maximum Concentration in Plasma) of MP-424
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
Time frame: Data were collected at Day1 to Day85
AUC 0-8h (Area Under the Concentration-time Curve From Time Zero to 8 Hours) of MP-424
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
Time frame: Data were collected at Day1 to Day85
Ctrough (Minimum Observed Concentration in Plasma) of MP-424
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
Time frame: Data were collected at Day1 to Day85
T1/2(Time of Half-Life) of MP-424
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
Time frame: Data were collected at Day1 to Day85
Antiviral Effects of TVR on HCV Were Assessed by Measuring Plasma HCV RNA Levels
HCV RNA concentrations were determined using the COBAS TaqMan HCV test (Roche Diagnostics). The linear dynamic range of the assay was 1.2-7.8 log10 IU/mL.
Time frame: 37 weeks
| Milestone | Group A (MP-424 High) | Group B (MP-424 Low) |
|---|---|---|
| Started | 10 | 10 |
| Completed | 6 | 6 |
| Not completed | 4 | 4 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Stopping criteria | 3 | 2 |
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
| μg/mL | Group A (MP-424 High) | Group B (MP-424 Low) |
|---|---|---|
| Day 1 (Group A,B:10 cases) | 1.62 ± 0.43 | 1.45 ± 0.83 |
| Day 14 (Group A,B:10 cases) | 3.96 ± 1.10 | 3.06 ± 0.90 |
| Day 85 (Group A: 6 cases, Group B: 7 cases) | 3.67 ± 0.87 | 3.16 ± 1.10 |
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
| hours | Group A (MP-424 High) | Group B (MP-424 Low) |
|---|---|---|
| Day 1 (Group A, B:10 cases) | 2.51 (2.25 to 6.00) | 2.54 (2.33 to 8.02) |
| Day 14 (Group A, B:10 cases) | 2.50 (2.42 to 5.75) | 2.45 (2.33 to 6.00) |
| Day 85 (Group A: 6 cases, Group B: 7 cases) | 3.24 (2.35 to 7.75) | 2.43 (2.33 to 4.00) |
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
| μg/mL | Group A (MP-424 High) | Group B (MP-424 Low) |
|---|---|---|
| Day 1 (Group A, B: 10 cases) | 7.53 ± 1.93 | 6.55 ± 3.73 |
| Day 14 (Group A: 9 cases, Group B: 10 cases) | 26.00 ± 6.77 | 19.94 ± 5.97 |
| Day 85 (Group A: 6 cases, Group B: 7 cases) | 25.00 ± 5.23 | 21.35 ± 6.88 |
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
| μg/mL | Group A (MP-424 High) | Group B (MP-424 Low) |
|---|---|---|
| Day1 (Group A,B: 10 cases) | 0.846 ± 0.500 | 0.681 ± 0.412 |
| Day14 (Group A: 9 cases, Group B:10cases) | 2.639 ± 0.556 | 1.914 ± 0.717 |
| Day85 (Group A: 6 cases, Group B:7cases) | 2.679 ± 0.355 | 2.105 ± 0.819 |
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
| hours | Group A (MP-424 High) | Group B (MP-424 Low) |
|---|---|---|
| Day1 (Group A: 7 cases, Group B: 8 cases) | 4.87 ± 2.12 | 4.03 ± 1.63 |
| Day14 (Group A: 8 cases, Group B: 9 cases) | 9.99 ± 4.37 | 10.00 ± 6.97 |
| Day85 (Group A: 6 cases, Group B: 7 cases) | 9.06 ± 3.98 | 6.22 ± 3.64 |
HCV RNA concentrations were determined using the COBAS TaqMan HCV test (Roche Diagnostics). The linear dynamic range of the assay was 1.2-7.8 log10 IU/mL.
| Log IU / mL | Group A (MP-424 High) | Group B (MP-424 Low) |
|---|---|---|
| Day 1_2.5h (Group A,B: 10 cases) | -0.190 ± 0.235 | -0.220 ± 0.329 |
| Day 1_4h (Group A,B: 10 cases) | -0.420 ± 0.264 | -0.390 ± 0.378 |
| Day 1_8h (Group A,B: 10 cases) | -1.300 ± 0.294 | -1.310 ± 0.309 |
| Day 1_16h (Group A,B: 10 cases) | -2.350 ± 0.458 | -2.480 ± 0.286 |
| Day 2 (Group A,B: 10 cases) | -3.010 ± 0.340 | -3.180 ± 0.220 |
| Day 3 (Group A,B: 10 cases) | -3.610 ± 0.453 | -3.790 ± 0.407 |
| Day 8 (Group A,B: 10 cases) | -4.840 ± 0.622 | -5.010 ± 0.551 |
| Day 14 (Group A,B: 10 cases) | -5.570 ± 0.579 | -5.800 ± 0.554 |
| Day 29 (Group A: 10 cases, Group B: 9 cases) | -5.860 ± 0.611 | -5.978 ± 0.519 |
| Day 43 (Group A: 8 cases, Group B: 8 cases) | -6.000 ± 0.573 | -5.994 ± 0.590 |
| Day 57 (Group A: 7 cases, Group B: 8 cases) | -5.986 ± 0.538 | -5.994 ± 0.539 |
| Day 86 (Group A: 6 cases, Group B: 7 cases) | -6.000 ± 0.588 | -6.114 ± 0.609 |
| Day 92 (Group A: 6 cases, Group B: 7 cases) | -6.000 ± 0.588 | -6.114 ± 0.609 |
| Day 99 (Group A: 6 cases, Group B: 7 cases) | -6.000 ± 0.588 | -5.471 ± 1.065 |
| Day 113 (Group A: 6 cases, Group B: 7 cases) | -5.917 ± 0.564 | -3.457 ± 2.591 |
| Day 141 (Group A: 6 cases, Group B: 7 cases) | -4.233 ± 2.455 | -3.000 ± 2.865 |
| Day 169 (Group A: 6 cases, Group B: 6 cases) | -3.100 ± 2.827 | -3.267 ± 3.067 |
| Day 197 (Group A: 6 cases, Group B: 6 cases) | -2.850 ± 2.947 | -3.283 ± 3.031 |
| Day 225 (Group A: 6 cases, Group B: 6 cases) | -2.633 ± 2.748 | -3.183 ± 3.140 |
| Day 253 (Group A: 6 cases, Group B: 6 cases) | -1.883 ± 3.177 | -3.100 ± 3.234 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A (MP-424 High) | — | 2/10 (20%) | 10/10 (100%) |
| Group B (MP-424 Low) | — | 2/10 (20%) | 10/10 (100%) |
| Event | Group A (MP-424 High) | Group B (MP-424 Low) |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/10 | 1/10 |
| Appetite disordersMetabolism and nutrition disorders | 0/10 | 1/10 |
| DizzinessNervous system disorders | 0/10 | 1/10 |
| VertigoEar and labyrinth disorders | 1/10 | 0/10 |
| Drug eruptionSkin and subcutaneous tissue disorders | 0/10 | 1/10 |
| Event | Group A (MP-424 High) | Group B (MP-424 Low) |
|---|---|---|
| Platelet count decreasedInvestigations | 10/10 | 10/10 |
| White blood cell count decreasedInvestigations | 9/10 | 10/10 |
| AnaemiaBlood and lymphatic system disorders | 9/10 | 8/10 |
| PyrexiaGeneral disorders | 6/10 | 8/10 |
| Protein total decreasedInvestigations | 0/10 | 8/10 |
| HeadacheNervous system disorders | 3/10 | 7/10 |
| RashSkin and subcutaneous tissue disorders | 7/10 | 7/10 |
| Blood lactate dehydrogenase increasedInvestigations | 3/10 | 7/10 |
| MalaiseGeneral disorders | 6/10 | 5/10 |
| Blood triglycerides increasedInvestigations | 6/10 | 5/10 |
| Age, Continuous(years) | Group A (MP-424 High) | Group B (MP-424 Low) | Total |
|---|---|---|---|
| Mean | 50.1 ± 6.8 | 54.3 ± 8.5 | 52.2 ± 7.8 |
| Sex: Female, Male(Participants) | Group A (MP-424 High) | Group B (MP-424 Low) | Total |
|---|---|---|---|
| Female | 4 | 6 | 10 |
| Male | 6 | 4 | 10 |
The record gives a start of Apr 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telaprevir · Peginterferon alfa-2b · Ribavirin